Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine

越来越明确的针对传染病的疫苗耐受性更好，但免疫原性更低，需要使用免疫佐剂才能达到最佳效果。佐剂公司的半合成皂素佐剂TiterQuil-1055 （TQL1055）已被证明对多种抗原有效，且无检测到的反应性。I期项目的目标是测试TQL1055是否可以增强流感疫苗的免疫原性和效力，并进行IND的稳定性研究。

Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenic, requiring use of an immunological adjuvant for best effect. Adjuvance's semi-synthetic saponin adjuvant TiterQuil-1055 (TQL1055) has demonstrated efficacy with a variety of antigens with no detectable reactogenicity. The objectives of the Phase I project are to test whether TQL1055 can enhance the immunogenicity and efficacy of influenza vaccines, and to conduct IND enabling stability studies.